Utah regulator keeps human review and acknowledges missing robust benefit evidence

For regulatory agencies, focus on the problem of supervising a bounded pilot while evidence is still developing. Engage the program director, relevant licensing specialists, privacy staff and evaluation leads. Ask which results are company-reported, who can inspect underlying interactions and what would stop expansion. A bounded engagement could design the oversight evidence register and reporting process. The value hypothesis is clearer decisions and traceability, not demonstrated patient benefit or reduced clinical labor. Do not present regulatory relief as a product endorsement or claim that absence of reported incidents proves safety.

Fit is an assurance layer around actions with a defined human review boundary. Map identity verification, proposed action, reviewer approval, escalation and downstream execution as separately testable steps. Prerequisites include authorized access to representative records, domain-specific reviewers and a documented phase policy. Test bypass attempts, conflicting information, unavailable reviewers and disclosure failures. A proposed proof of value should demonstrate that prohibited actions cannot reach downstream systems and that escalation is usable. The public page provides neither implementation details nor independent adversarial results; it cannot establish a particular model's reliability or justify unsupervised authority.

Build a versioned evidence register, reporting schedule and escalation playbook before changing pilot permissions. The regulator owns continuation decisions; the company owns service operation; qualified reviewers assess cases. Dependencies include access to reviewable data, privacy decisions and evaluator capacity.

Proposed acceptance criteria

every sampled action traces to required approval, all report fields reconcile to records, and phase changes have written authorization and resolved critical findings. Train support staff to route complaints and preserve evidence. Risks include stale public status, altered measurement scope, weak independent review and confusing reported non-events with verified absence of harm.